HOT NEWS
Bayer HealthCare joins forces with Stroke Alliance for Europe » Ahead of the "Move for Health Day" (10 May) and the "European Stroke Day" (14 May), the Stroke Allia...
Sanofi strengthens its French-German partnership » Sanofi (EURONEXT: SAN and NYSE: SNY) announced its involvement in two major Franco-German projects ...
Merck Serono to finance the launch of the EspeRare Foundation » Merck Serono, a division of Merck, Darmstadt, Germany, today announced the launch of the EspeRare Fo...
Bayer HealthCare to broaden strategic alliance with German Cancer Research Cente... » Bayer HealthCare (Bayer) and the German Cancer Research Center (DKFZ) will extend their successful s...
AstraZeneca and Karolinska Institutet to create Integrated Translational Researc... » AstraZeneca and the Swedish medical university Karolinska Institutet announced today their intention...
Innovative cervical screening app launches in UK and Ireland » The new Roche cobas® HPV Test app for iPad, which provides essential information about cervical can...
Roche obtains EU approval for PERJETA, a new personalised treatment for aggressi... » Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency (EMA) has appr...
Novartis receives EU approval for Ilaris® in patients suffering acute gouty art... » Novartis announced that the European Commission (EC) has approved llaris (canakinumab, ACZ885) in th...
Genzyme Receives Company Award from European Organisation for Rare Diseases (EUR... » Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), ahas received a Company Award from EURORDIS...
Bayer supports innovative drug discovery in Europe » Bayer HealthCare initiated and will coordinate a newly founded pan-European consortium, named Europe...
Amgen
AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. For more information, please visit http://www.amgen.com

Amgen RSS Channel
Title Filter     Display # 
# Article Title Hits
1 Amgen to acquire Mustafa Nevzat, a leading privately held Turkish pharmaceutical company 4217
2 XGEVA® (Denosumab) Granted Marketing Authorization in the European Union 6503
3 Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination with Chemotherapy 8568
4 Amgen's First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion 8728
5 Amgen Statement on CHMP Opinion on Vectibix(R) (Panitumumab) 9065
6 Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 10634
7 Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial 11086
8 Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union 14463
9 Amgen Receives CHMP Positive Opinion for Prolia(TM) (Denosumab) in the European Union 11203
10 Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 11514